Business Wire

Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy

SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...
Business Wire

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

Patients should not use Lucentis if they have an infection in or around the eye or are allergic to Lucentis or any of its ingredients. Lucentis is a prescription medication given by injection into the ...
Reuters

Study shows Lucentis safer than Avastin - Novartis

ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...
Medscape

FDA Approves Ranibizumab for Diabetic Macular Edema

August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...
Seeking Alpha

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of ...

- COLUMBUS AMD trial was published in the journal Ophthalmology and demonstrated the clinical equivalence of CIMERLI™ to Lucentis® with a comparable safety and immunogenicity profile - REDWOOD CITY, ...
JD Supra

Coherus Announces FDA Approval of CIMERLI (ranibizumab-eqrn)

On August 2, 2022, Coherus BioSciences, Inc. announced that the FDA approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar interchangeable with LUCENTIS ® (ranibizumab injection) for all five ...